Doctiplus - We are allways here!
Diabetes (Type 2)
Weekly Report
- 39 new clinical trials registered across 10 countries.
- 1,972 trials actively recruiting patients worldwide.
- Notable trial: Chinese Overweight/Obesity Cohort: Metabolic & Comorbidity Risks (25974 patients).
- 339 new research papers published.
- Drug safety: Most reported effect across tracked medications (metformin, semaglutide, sitagliptin, empagliflozin, insulin glargine) was Off Label Use.
- No active drug recalls for tracked medications this week.
The week in numbers
Trials by country
Trials by phase
New clinical trials registered this week for Diabetes (Type 2). Each trial links to its full record on ClinicalTrials.gov where you can find eligibility criteria, locations, and contact information.
This week's new registrations
39 trials registered for Diabetes (Type 2). Each links to its full record on ClinicalTrials.gov.
| # | Trial ↓ | Phase ↕ | Status ↕ | Enrollment ↕ | Country ↕ |
|---|---|---|---|---|---|
| 01 | Comprehensive Intervention to Promote Adjustment in Adolescents With Type 1 Diabetes and Their Parents During Transfer of Health Care Responsibility Diabetes (Type 2) · Universidad de la Sabana (NCT07886307) | Other | Completed | 34 | Colombia |
| 02 | Effects Of Core Canister Training in Pregnant Women With History of Gestational Diabetes Mellitus Diabetes (Type 2) · University of Lahore (NCT07889791) | Other | Recruiting | 90 | Pakistan |
| 03 | Continuous Glucose Monitoring and Dietary Self-Management in Adults in Namwon Diabetes (Type 2) · Ji-Yeob Choi (NCT07890740) | Other | Not Yet Recruiting | 860 | South Korea |
| 04 | Randomized Trial of the RIGHTEST iFree 2 CGM System for Glycemic Control in Adults With Diabetes Mellitus Diabetes (Type 2) · Bionime Corporation (NCT07889375) | Other | Recruiting | 324 | Taiwan |
| 05 | Digital Health Literacy and Diabetes Management in Type 2 Diabetes Diabetes (Type 2) · Abant Izzet Baysal University (NCT07888972) | Other | Not Yet Recruiting | 348 | Turkey (Türkiye) |
| 06 | Different Diets in Different Diabetes - 4DI PLAN'EAT Pilot Study Diabetes (Type 2) · University of Bologna (NCT07887477) | Other | Active Not Recruiting | 101 | Italy |
| 07 | AI-CARE: A Novel AI-Driven Mobile Insulin Calculator Integrating Image- Based Carbohydrate Estimation and CGM Diabetes (Type 2) · Tan Tock Seng Hospital (NCT07884526) | Other | Not Yet Recruiting | 48 | Singapore |
| 08 | Perineural Botulinum Toxin Injection Versus Oral Duloxetine in Relief of Foot Pain in Painful Peripheral Diabetic Neuropathy Diabetes (Type 2) · Assiut University (NCT07882238) | Phase 2 | Not Yet Recruiting | 56 | N/A |
| 09 | Iopidine to Decrease Intraocular Pressure Rise After Injections Diabetes (Type 2) · Retina Consultants of Delmarva (NCT07891910) | Phase 4 | Not Yet Recruiting | 120 | United States |
| 10 | A Study of EloraTZP in Adult Participants With Obesity or Overweight and Type 2 Diabetes Diabetes (Type 2) · Eli Lilly and Company (NCT07881458) | Phase 3 | Not Yet Recruiting | 1,000 | United States |
| 11 | A Study of LY4167586 in Participants With Obesity or Overweight With or Without Type 2 Diabetes Diabetes (Type 2) · Eli Lilly and Company (NCT07881887) | Phase 1 | Not Yet Recruiting | 617 | United States |
| 12 | Unmasking Diabetes in Dialysis With Continuous Glucose Monitoring Diabetes (Type 2) · Emory University (NCT07880795) | Other | Not Yet Recruiting | 180 | United States |
| 13 | Metabolic Effects of Switching From Injectable Semaglutide to Tirzepatide Diabetes (Type 2) · LMC Diabetes & Endocrinology Ltd. (NCT07889453) | Other | Active Not Recruiting | 650 | Canada |
| 14 | Scaling up the DSMES Learning Collaborative Diabetes (Type 2) · Mary Lacy (NCT07888179) | Other | Not Yet Recruiting | 96 | United States |
| 15 | Construction and Empirical Research of a Risk Prediction Model for Preventing Lower Extremity Arteriosclerosis Obliterans in Diabetic Patients Based on the HAPA Model Diabetes (Type 2) · Second Affiliated Hospital of Nanchang University (NCT07881588) | Other | Recruiting | 154 | China |
| 16 | Tolerability and Safety of Nano-Tocotrienols Diabetes (Type 2) · University of Malaya (NCT07888426) | Phase 2 | Not Yet Recruiting | 360 | Malaysia |
| 17 | Lean Mass Changes With Semaglutide in Adults With Type 1 Diabetes and Overweight/Obesity. Diabetes (Type 2) · McGill University Health Centre/Research Institute of the McGill University Health Centre (NCT07891156) | Phase 3 | Recruiting | 40 | Canada |
| 18 | A Study of EloraTZP in Adult Participants With Obesity Without Type 2 Diabetes Diabetes (Type 2) · Eli Lilly and Company (NCT07881432) | Phase 3 | Not Yet Recruiting | 2,115 | United States |
| 19 | Effects of Mango on Insulin Sensitivity in Prediabetes Diabetes (Type 2) · Clinical Nutrition Research Center, Illinois Institute of Technology (NCT07886372) | Other | Not Yet Recruiting | 64 | United States |
| 20 | Transitioning Recently Admitted Patients With Non-Insulin and Insulin-treated Type 2 Diabetes to Innovative Glucose Monitoring Diabetes (Type 2) · University of Cincinnati (NCT07890818) | Other | Not Yet Recruiting | 218 | United States |
| 21 | Impact of Diabetes on Patients With Osteoporotic Vertebral Compression Fractures After Vertebral Augmentation Diabetes (Type 2) · The First Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine (NCT07884149) | Other | Completed | 360 | China |
| 22 | LIfestyle MEtabotype Study B (LIME-B) Diabetes (Type 2) · German Institute of Human Nutrition (NCT07888257) | Other | Recruiting | 300 | Germany |
| 23 | Effects of Increased Water Intake on Hormonal Response, Hydration Status, and Physical Function in Low-drinking Older Adults Diabetes (Type 2) · Polytechnic University of Santarém (NCT07892742) | Other | Not Yet Recruiting | 38 | N/A |
| 24 | A Study to Investigate the Effect of LY4086940 Versus Placebo in Participants With Obesity or Overweight and Without Type 2 Diabetes Diabetes (Type 2) · Eli Lilly and Company (NCT07890376) | Phase 2 | Not Yet Recruiting | 460 | United States |
| 25 | RIGHTEST iFree 2 CGM in Pregnant Women With Diabetes Study Diabetes (Type 2) · Bionime Corporation (NCT07889388) | Other | Recruiting | 104 | Germany |
| 26 | Effectiveness and Safety of the RIGHTEST™ CGM System for Blood Glucose Management in Persons With Diabetes Mellitus Diabetes (Type 2) · Bionime Corporation (NCT07888582) | Other | Completed | 50 | Germany |
| 27 | A Phase 2 Two-Part Study of Oral PS1 in Healthy Volunteers and Adults With Newly Diagnosed Type 1 Diabetes Diabetes (Type 2) · Pharmasaga Co. Ltd. (NCT07889505) | Phase 2 | Not Yet Recruiting | 36 | N/A |
| 28 | MENA/Levant Epidemiological, Registry of Immunological & Clinical Traits (MERIT) Diabetes (Type 2) · Axiom Bioregistry (NCT07892651) | Other | Not Yet Recruiting | 5,000 | Jordan |
| 29 | Effects of Adding a Registered Dietitian to Rural Community Healthy Behavior Support Services for Management of Type 2 Diabetes Diabetes (Type 2) · Indiana University (NCT07883343) | Other | Completed | 14 | United States |
| 30 | Chinese Overweight/Obesity Cohort: Metabolic & Comorbidity Risks Diabetes (Type 2) · Shanxi Bethune Hospital (NCT07884903) | Other | Not Yet Recruiting | 25,974 | China |
| 31 | Prevalence and Associated Factors of High BMI and Periodontitis in Thai Adults Aged Under 60 Years Diabetes (Type 2) · Mahidol University (NCT07880717) | Other | Recruiting | 93 | Thailand |
| 32 | Verapamil In Preclinical Type 1 Diabetes Diabetes (Type 2) · Assistance Publique - Hôpitaux de Paris (NCT07880769) | Phase 3 | Not Yet Recruiting | 50 | France |
| 33 | Effect of SGLT2 Inhibitor on Metabolic-Dysfunction-Associated Fatty Liver Disease in Patients With Insulin Resistance Diabetes (Type 2) · Sherihan AboElyazed Mohamed Khalil (NCT07891234) | Phase 4 | Not Yet Recruiting | 66 | Egypt |
| 34 | Preventive Effectiveness of Primary Care Physician-led CGM-supported Comprehensive Intervention on Cardio-metabolic-immune Diseases in Community Patients With Type 2 Diabetes (Community Diabetes Control Project) Diabetes (Type 2) · Xiangya Hospital of Central South University (NCT07885904) | Other | Not Yet Recruiting | 15,400 | China |
| 35 | HUGO-SLEEVE: Evaluating the Feasibility of Robotic Sleeve Gastrectomy With a New Platform Diabetes (Type 2) · Universitätsklinikum Hamburg-Eppendorf (NCT07884994) | Other | Recruiting | 50 | Germany |
| 36 | Modulatory Effects of Resveratrol Supplement Along With and Without Low Glycemic Index Diet Among Obese Patients With Diabetic Nephropathy Diabetes (Type 2) · University of Lahore (NCT07891975) | Other | Completed | 102 | Pakistan |
| 37 | Impact of AI-Based Breath Ammonia Kidney Function Results on Clinical Pharmacist Medication Recommendations Diabetes (Type 2) · Shanghai Pudong Hospital (NCT07888855) | Other | Not Yet Recruiting | 380 | China |
| 38 | Hypoglycemia Risk Assessment in Elderly and Senile Female Patients With Type 2 Diabetes Mellitus Diabetes (Type 2) · Samara State Medical University (NCT07887334) | Other | Completed | 200 | Russia |
| 39 | A Clinical Study to Evaluate the Effects of Enicepatide Versus Tirzepatide in Participants With Type 2 Diabetes and Inadequate Blood Sugar Control on Oral Glucose-Lowering Medications Diabetes (Type 2) · Hoffmann-La Roche (NCT07889648) | Phase 3 | Not Yet Recruiting | 948 | N/A |
Adverse event reports
Adverse drug event reports compiled from the FDA's FAERS database for medications commonly prescribed for Diabetes (Type 2). These reports reflect what patients and healthcare providers have reported — they do not confirm a drug caused the effect.
Reports by drug
| Drug | Top effect | Count |
|---|---|---|
| metformin | Diarrhoea | 2,240 |
| semaglutide | Nausea | 2,963 |
| sitagliptin | Nausea | 330 |
| empagliflozin | Nausea | 823 |
| insulin glargine | Off Label Use | 4,775 |
Recalls & safety notices
FDA drug recall notices for medications related to Diabetes (Type 2). If your medication is listed, contact your pharmacist or visit fda.gov/safety/recalls for guidance. No recall listed does not guarantee safety — always consult your healthcare provider.
No active drug recalls for tracked medications this period.
Published research
Recently published peer-reviewed studies related to Diabetes (Type 2), sourced from PubMed and Semantic Scholar. Click any title to read the full paper, or expand the abstract for a quick summary.
| # | Study | Journal | Date | Source |
|---|---|---|---|---|
| 01 |
Nanocarriers for On-Demand Insulin Aspart Delivery: Integrated Control of Postprandial and Basal Glycemia in Type 2 Diabetic Mice.
View abstractType 2 diabetes mellitus demands coordinated control of fasting and postprandial glycemia, and current clinical rapid-acting insulin aspart (IAsp) suffers from short action duration and hypoglycemia-related risks. We describe a glucose-sensitive insulin delivery system based on rigid amphiphilic methoxy poly(ethylene glycol)-polysalicylate (mPEG-PSA) copolymers synthesized by controlled ring-opening polymerization of salicylic acid O-carboxyanhydride, with a structure substantially different from conventional aliphatic polyesters. The 100-150 nm nanoparticles possessed favorable colloidal stability, ∼85% encapsulation efficiency and ∼20% drug loading, and IAsp bioactivity was well preserved. In vitro release followed glucose-dependent kinetics tuned by PSA hydrophobicity. In streptozotocin-induced diabetic mice, IAsp@mPEG-PSA restored euglycemia within 0.5 h and maintained normoglycemia for up to 10 h without hypoglycemia, outperforming free IAsp and mPEG-PLA formulations in this animal model. The nanosystem realized glucose-activated on-demand insulin release to suppress repeated glucose spikes, accomplishing combined postprandial and basal glycemic regulation in rodents. This study presents mPEG-PSA as a promising polymeric candidate for glucose-responsive insulin delivery. |
ACS applied bio materials | 2026 Oct 25 | PubMed |
| 02 |
Saikosaponin A promotes diabetic wound healing by suppressing NLRP3 inflammasome-associated macrophage pyroptosis and modulating mitophagy-related signaling.
View abstractBACKGROUND: Diabetic wounds are characterized by persistent inflammation and impaired tissue repair. Saikosaponin A (SSA) exhibits anti-inflammatory and cytoprotective activities, but its effects on macrophage pyroptosis and mitophagy-related signaling during diabetic wound healing remain unclear. METHODS: In vivo, streptozotocin (STZ)-induced diabetic mice with full-thickness wounds were treated locally with SSA, and wound repair, inflammatory responses, macrophage pyroptosis-associated signaling, and AMPK/mitophagy-related pathways were evaluated. In vitro, RAW264.7 macrophages were exposed to high glucose (HG), with an equiosmolar mannitol control, and a macrophage-fibroblast co-culture system was used to assess fibroblast responses. Compound C was used to investigate the involvement of AMPK signaling. RESULTS: Diabetic mice exhibited delayed wound healing, enhanced GSDMD-associated signaling, and increased local and systemic inflammation. HG increased GSDMD cleavage, PI positivity, LDH release, and IL-1β/IL-18 secretion, whereas the mannitol control did not reproduce these changes. Fibroblasts co-cultured with HG-exposed macrophages showed increased P53/P21 expression, reduced EdU incorporation, and impaired migration. SSA accelerated wound closure, improved tissue remodeling, and reduced NLRP3/caspase1/GSDMD-associated inflammatory responses. SSA also increased AMPK phosphorylation and PINK1/Parkin- and LC3-related signaling while reducing P62 accumulation. Compound C attenuated these SSA-associated changes. CONCLUSION: SSA promotes diabetic wound repair and is associated with activation of AMPK/mitophagy-related signaling and suppression of NLRP3/GSDMD-associated macrophage pyroptotic responses. |
Molecular biology reports | 2026 Oct 25 | PubMed |
| 03 | Correction: Targeting the IRE1α/XBP1 pathway in type 2 diabetes mellitus: from ER stress signaling to therapeutic opportunity. | Molecular biology reports | 2026 Oct 25 | PubMed |
| 04 |
O-linked β-N-acetylglucosamine homeostasis in brain health and disease: From physiology to neurodevelopmental and neurodegenerative disorders.
View abstractProtein O-GlcNAcylation is a dynamic and reversible post-translational modification that functions as a central nutrient-sensing mechanism linking cellular metabolism to protein function. Controlled by the opposing activities of O-linked β-N-acetylglucosamine transferase and O-GlcNAcase, O-GlcNAcylation regulates thousands of nuclear, cytoplasmic, synaptic, and mitochondrial proteins involved in gene expression, neuronal differentiation, synaptic plasticity, proteostasis, mitochondrial homeostasis, and neuroimmune signaling. The brain exhibits particularly high O-linked β-N-acetylglucosamine activity, reflecting its exceptional metabolic demands and the need to rapidly couple nutrient availability with neuronal function. Emerging evidence demonstrates that precise regulation of O-linked β-N-acetylglucosamine cycling is indispensable throughout the lifespan, from embryonic neurodevelopment to healthy brain aging. Conversely, disruption of O-linked β-N-acetylglucosamine homeostasis caused by genetic defects, metabolic disturbances, or environmental stress contributes to neurodevelopmental disorders. In the aging brain, impaired glucose metabolism and insulin resistance reduce O-GlcNAcylation, promoting mitochondrial dysfunction, neuroinflammation, proteostasis failure, and the accumulation of pathogenic proteins. Consequently, dysregulated O-linked β-N-acetylglucosamine signaling has emerged as a convergent mechanism underlying brain disorders spanning neurodevelopment to neurodegeneration. Although clinical translation remains challenging, growing evidence supports O-GlcNAcylation as a master regulator of brain homeostasis and a promising therapeutic target for neurological disorders. Collectively, this review highlights O-linked β-N-acetylglucosamine signaling as a molecular bridge connecting early brain development, adulthood, and aging, providing an integrated framework for understanding brain physiology and disease. |
Neural regeneration research | 2026 Oct 24 | PubMed |
| 05 |
Screening for metabolic dysfunction-associated steatotic liver disease in type 2 diabetes patients using the fibrosis-4 score in medina-retrospective study.
View abstractBACKGROUND: Type 2 diabetes mellitus (T2DM) is a global health problem closely linked to metabolic dysfunction-associated steatotic liver disease (MASLD) and advanced fibrosis. The fibrosis-4 (FIB-4) index is a standard noninvasive tool for estimating fibrosis risk. This study aimed to describe the demographics, metabolic parameters, comorbidities, and T2DM duration of patients in Medina and to screen for MASLD using the FIB-4 score. METHODS: At King Salman Diabetic Center, Medina, Saudi Arabia, a cross-sectional study was conducted among 280 T2DM patients aged >35 years. Data were gathered from electronic medical records. FIB-4 levels were calculated and categorized as low (<1.3), intermediate (1.3-2.67), or high (>2.67) risk. Statistical analysis was performed with IBM SPSS Statistics 30, with < 0.05 considered significant. RESULTS: A total of 87.9%of the 280 participants had low-risk FIB-4 scores, 11.4% had intermediate risk scores, and 0.7% had high risk scores. Individuals with FIB-4 ≥ 1.3 were predominantly male (64.7% . 43.5%, = 0.0271) and older (median age: 56 . 52 years, = 0.009). The risk groups were not significantly different in terms of body mass index (BMI) and lipid profiles, glycemic control, hypertension, or diabetes duration. CONCLUSION: A significant proportion of T2DM patients had intermediate- or high-risk FIB-4 scores. These findings endorse the need for screening for liver fibrosis in T2DM patients, particularly those at increased risk. Early detection and appropriate management are essential to prevent progression to advanced liver disease. |
PeerJ | 2026 | PubMed |
| 06 |
Metformin Use Is Associated With Reduced Rates of Primary Nerve Decompression Surgery and Revision in Type 2 Diabetes: A Retrospective Cohort Study.
View abstractPURPOSE: Type 2 diabetes mellitus is a risk factor for compressive neuropathy. The purpose of this study was to determine whether metformin use is associated with reduced rates of compressive neuropathy, primary nerve decompression surgery, and revision after carpal tunnel release and cubital tunnel release, while controlling for concurrent diabetes medications. METHODS: We performed a retrospective cohort study using the TriNetX federated research network. Adults with type 2 diabetes mellitus were stratified by metformin exposure, defined as at least 10 prescriptions over 5 years. The primary outcomes were incident compressive neuropathy and nerve decompression surgery. In a unilateral revision cohort, the outcome was ipsilateral revision between 30 days and 5 years after the index procedure. One-to-one propensity score matching balanced cohorts on demographics, comorbidities, and concurrent diabetes medications. Four prespecified medication-stratified sensitivity analyses addressed insulin, sodium-glucose cotransporter-2 inhibitors, and glucagon-like peptide-1 receptor agonists. Carpal tunnel release and cubital tunnel release revision results were pooled via fixed-effect meta-analysis. RESULTS: After matching, the primary analysis included 260,823 pairs. Metformin users had lower rates of nerve decompression surgery (0.60% vs 0.72%; odds ratio, OR, 0.831 [0.776-0.889]) and compressive neuropathy diagnosis (2.78% vs 3.05%; OR, 0.909 [0.879-0.941]). The surgery-level association was stronger without concurrent insulin (OR, 0.727 [0.662-0.799]) and attenuated to nonsignificance with concurrent insulin (OR, 0.948 [0.836-1.076]), though the diagnosis-level association persisted. Among patients with unilateral carpal or cubital tunnel syndrome, ipsilateral revision was less frequent in metformin users (pooled OR, 0.711 [0.533-0.950]). Metformin users also had lower vitamin B12 levels (mean, 646.4 vs 707.4 pg/mL), consistent with sustained metformin exposure. CONCLUSIONS: Metformin use was associated with reduced incidence of nerve decompression surgery and ipsilateral revision after carpal tunnel release and cubital tunnel release in patients with type 2 diabetes mellitus, with directionally consistent effects across sensitivity analyses. These findings suggest that maintaining metformin therapy may carry benefit beyond glycemic control. Prospective studies are needed to validate these findings. TYPE OF STUDY/LEVEL OF EVIDENCE: Prognostic II. |
Journal of hand surgery global online | 2027 Jan | PubMed |
| 07 |
Potential Association of BRCA Mutation and Lymphocytic Lobulitis.
View abstractLymphocytic lobulitis (LL) is a rare fibroinflammatory breast lesion historically associated with long-standing Type 1 diabetes mellitus and autoimmune conditions. Recent evidence suggests possible links between LL and hereditary breast cancer syndromes, particularly BRCA mutations. We present the case of a BRCA1 mutation carrier who developed bilateral lymphocytic lobulitis with B-cell predominance, discuss its clinicopathologic features, and review current literature on the intersection of autoimmune, metabolic, and genetic risk pathways. |
Clinical case reports | 2026 Nov | PubMed |
| 08 |
Metabolite Profiling, Modulation of Glucose Metabolism and Antioxidant Activity Reveals the Protective Effect of Sulfated Polysaccharides From Gracilaria gracilis in Hepatic Tissues of Type 2 Diabetic Rats.
View abstractDiabetic hepatopathy is one of the complications of Type 2 diabetes (T2D), and it's a major cause of mortality and morbidities associated with the disease. Seaweeds are good sources of bioactive compounds of medicinal importance and have shown potential as an alternative therapy for the treatment of diabetes. This study assessed the protective effect of sulfated polysaccharides (SPs) from a red seaweed specie () against diabetic hepatopathy and its potential biochemical mechanisms in rats with T2D. SPs from (150 and 300 mg/kg bodyweight [bw]) were given orally to two groups of T2D rats, respectively. The diabetic and normal control groups were given water, while metformin served as the standard. Hepatic activities of glucose metabolic enzymes and oxidative stress parameters were assessed in the liver. Hepatic metabolites in liver tissues from the different groups were analyzed using chromatographic techniques. Induction of T2D led to significant decrease in glutathione level, superoxide dismutase, catalase, glutathione peroxidase, glutathione reductase, glutathione S-transferase activities, while an increase in fructose-1.6-biphosphatase, glucose 6-phosphatase and glycogen phosphorylase activities were observed in hepatic tissues. Glucose, lipid and amino acid metabolic pathways, and their metabolites were also dysregulated on induction of T2D. Treatment with SPs led to the reversal of the glutathione and malondialdehyde levels, as well as antioxidant enzyme activities, Furthermore a significant improvement in glucose, lipid, and amino acid metabolisms were observed in hepatic tissues of SPs treated diabetic rats. Our findings showed that SPs from exhibited protective effects against diabetic hepatopathy in T2D by attenuating lipotoxicity, oxidative stress, with concomitant improved glucose, lipid and amino acid metabolisms. |
Food science & nutrition | 2026 Oct | PubMed |
| 09 |
Relative handgrip strength and cardiometabolic multimorbidity among chinese middle-aged and older adults: mediation by metabolic and inflammatory pathways.
View abstractAlthough skeletal muscle decline is implicated in cardiometabolic diseases, the precise mechanistic pathways and the prognostic superiority of relative over absolute handgrip strength for cardiometabolic multimorbidity (CMM) remain incompletely quantified. This nationally representative cross-sectional study included 6,839 middle-aged and older Chinese adults from the 2015 China Health and Retirement Longitudinal Study. We evaluated the associations of relative handgrip strength (RHGS) and absolute grip strength with CMM using multivariable logistic and Poisson regressions. Causal mediation analysis was employed to dissect the pathways linking RHGS to CMM. Results demonstrated that a 1-standard deviation decrease in RHGS was robustly associated with a 68% increased risk of prevalent CMM (OR = 1.68, 95% CI: 1.49-1.89) and accelerated concurrent disease accumulation. Strikingly, substituting RHGS with BMI-adjusted absolute grip strength completely abolished these protective associations (OR = 1.09, = 0.148), exposing the artifactual confounding of body size on gross muscle force. Furthermore, mediation profiling revealed that the deleterious impact of RHGS decline on CMM was predominantly driven by networked metabolic dysfunction-specifically atherogenic lipid dysmetabolism (AIP, 20.0%) and insulin resistance (TyG index, 19.8%)-whereas systemic inflammation (CRP) exerted a marginal mediating effect (1.8%). In conclusion, RHGS, rather than absolute grip strength, serves as a paramount and reliable clinical indicator of cardiometabolic resilience. These findings suggest that RHGS is a potentially useful marker for cardiometabolic risk assessment, while prospective studies are needed to evaluate its clinical utility. |
3 Biotech | 2026 Nov | PubMed |
| 10 |
HbA1c and LDL-C Time in Therapeutic Range: A Study on All-Cause Mortality in Older Adults with Type 2 Diabetes Mellitus and Chronic Kidney Disease.
View abstractINTRODUCTION: Whether long-term attainment of glycated hemoglobin (HbA1c) and low-density lipoprotein cholesterol (LDL-C) targets improves prognosis in older adults with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD) remains unclear. We used time in therapeutic range (TTR) to quantify sustained glycemic and lipid control and examined its association, and interaction, with all-cause mortality. RESEARCH DESIGN AND METHODS: This retrospective multicenter cohort study, based on the Tianjin Health Big Data Platform, included 2005 older (≥65 years) and 5973 younger (<65 years) adults with T2DM-CKD. HbA1c-TTR (target <7.0%) and LDL-TTR (target <1.8 mmol/L) were calculated using the Rosendaal method. After Cox-LASSO covariate selection, multivariable Cox models with and without an interaction term were built, supplemented by RCS, subgroup analyses, and landmark and time-varying covariate sensitivity analyses. RESULTS: Over a median follow-up of 4.56 years, 211 older adults (10.5%) died. Without an interaction term, LDL-TTR (per 10-percentage-point increase) was associated with lower mortality (HR 0.934, P=0.003), while HbA1c-TTR was not (HR 0.983, P=0.459); with the interaction term, the HbA1c-TTR × LDL-TTR interaction was significant (HR 1.016, P=0.006). Adjusted RCS showed a significant nonlinear association for LDL-TTR (P nonlinear=0.020) but not for HbA1c-TTR overall (P=0.231). In the younger cohort, both main effects were significant, but the interaction was not (P=0.124). The interaction remained significant in the time-varying covariate model (HR 1.013, P=0.019) but not in the landmark analysis or under the alternative 6.5-8.0% HbA1c definition, under which LDL-TTR's main effect remained significant. CONCLUSIONS: In older adults with T2DM and CKD, higher LDL-TTR was independently associated with lower mortality, and a significant HbA1c-TTR × LDL-TTR interaction suggested that the inverse association of one TTR measure with mortality was attenuated at higher levels of the other. This interaction was absent in the younger cohort and under an alternative HbA1c target (6.5-8.0%), and was inconsistent across sensitivity analyses (significant with time-varying covariates, HR 1.013, P=0.019; non-significant in a landmark analysis, P=0.968). These exploratory findings do not support changing current management targets and require prospective validation. |
Clinical interventions in aging | 2026 | PubMed |
| 11 |
Real-World Evaluation of a Near-Infrared Spectroscopy-based Noninvasive Glucose Monitoring Device in Adults With Type 2 Diabetes.
View abstractBACKGROUND: Self-monitoring of blood glucose remains widely used in many individuals with type 2 diabetes (T2D), although the burden of capillary testing often limits the frequency of measurements. Noninvasive technologies may improve glucose monitoring. This study evaluated the analytical performance and applicability of a near-infrared spectroscopy-based noninvasive glucose monitoring device. METHODS: In this prospective, open-label clinical investigation, 52 adults with T2D performed 4 daily paired glucose measurements for more than 21 days using the investigational device and a reference capillary glucometer (Ascensia Contour Next). Following individualized calibration (10 paired measurements), post-calibration measurements within the 70 to 400 mg/dL range were included in the primary analysis. Accuracy was assessed using a combined mean absolute difference/mean absolute relative difference (MAD/MARD) metric, Parkes consensus error grid (CEG), and DTS error grid analyses. RESULTS: Forty-eight participants were included in the primary analysis, contributing 2,616 paired post-calibration measurements. The mean age was 58.0 ± 9.9 years, and 31.3% were female. The overall combined MAD/MARD value was 16.3, calculated by applying MAD to paired measurements with reference glucose values <100 mg/dL and MARD to paired measurements with reference glucose values ≥100 mg/dL. Overall, 69.8%, 86.3%, and 94.5% of measurements were within ±20%, ±30%, and ±40% of reference values, respectively. Parkes CEG analysis classified 69.9% of measurements in zone A, 29.1% in zone B, 1.0% in zone C, and none in zones D or E. Accuracy improved after the first week. No device-related adverse events were reported. CONCLUSION: The device demonstrated a favorable clinical risk profile, stable analytical performance, and good safety under real-world conditions. Although analytical precision remains lower than current continuous glucose monitoring systems, its fully noninvasive design supports further development as a complementary monitoring strategy for individuals with T2D unwilling or unable to use invasive monitoring technologies. TRIAL REGISTRATION: ClinicalTrials.gov (NCT07075796). |
Journal of diabetes science and technology | 2026 Oct 25 | PubMed |
| 12 |
Performance and Safety of a Continuous Glucose Monitoring System in Pregnant Women With Gestational Diabetes Mellitus: A Multicenter, Open-Label Trial.
View abstractBACKGROUND: Continuous glucose monitoring (CGM) is increasingly important in pregnancies complicated by diabetes, where strict glycemic control is essential to prevent adverse outcomes such as fetal macrosomia and preterm birth. In gestational diabetes mellitus (GDM)-which accounts for most of the diabetes in pregnancy-maternal hyperglycemia is the primary clinical concern. This study evaluated the accuracy and safety of a factory-calibrated CGM system over 15 days in pregnant women with diabetes, with most having GDM. METHODS: This prospective, multicenter, open-label trial enrolled 60 pregnant women (95% GDM, 3.3% type 1 diabetes, 1.7% type 2 diabetes). Each participant wore 2 sensors simultaneously, 1 on each upper arm, for up to 15 days. Venous blood glucose reference values were obtained using a Biosen C-line GP+ analyzer. Accuracy was assessed by 20/20% agreement rate, Diabetes Technology Society (DTS) error grid analysis, and mean absolute relative difference (MARD). Safety and usability were also evaluated. RESULTS: A total of 2901 matched CGM-reference pairs were analyzed (1451 from left-arm sensors, 1450 from right-arm sensors). The 20/20% agreement rate was 96.6% (95% CI, 95.6%-97.5%) for the left arm and 96.8% (95% CI, 95.8%-97.7%) for the right arm. The overall MARD was 7.72% (95% CI, 7.33%-8.11%) for the left arm and 7.66% (95% CI, 7.27%-8.05%) for the right arm. CONCLUSION: The CGM system demonstrated accurate, stable, and safe glucose monitoring over 15 days in pregnant women with predominantly GDM. Its strong performance supports its utility as a reliable tool for glucose monitoring during pregnancy. |
Journal of diabetes science and technology | 2026 Oct 25 | PubMed |
| 13 |
Prediabetes and diabetes as drivers of fibrosis in MASLD: roles of obesity, adipose tissue dysfunction and insulin resistance.
View abstractAIMS/HYPOTHESIS: Prediabetes and type 2 diabetes have been associated with more severe metabolic dysfunction-associated steatotic liver disease (MASLD), but not all individuals have the same risk and the metabolic drivers remain incompletely understood. To understand why, we examined the roles of obesity, adipose tissue dysfunction and insulin resistance in the development of significant liver fibrosis (fibrosis stage ≥F2) in adults across the glycaemic spectrum. METHODS: We performed a prospective, cross-sectional study in a real-world setting of adults attending primary care or endocrinology/diabetes clinics. Transient elastography was used to diagnose steatosis (controlled attenuation parameter ≥274 dB/m) and clinically significant liver fibrosis (vibration-controlled transient elastography liver stiffness measurement ≥8.2 kPa). When ≥F2 was suspected, MR-based imaging or liver biopsy was used to improve stratification. MASLD and significant fibrosis were compared across glycaemic and BMI categories and severity of insulin resistance (HOMA-IR; predominantly hepatic) and adipose tissue insulin resistance (assessed by adipose tissue insulin resistance [Adipo-IR]). RESULTS: Among the 1446 participants, the prevalence of MASLD increased across glycaemic categories from 39% in participants with normoglycaemia, to 55% in those with prediabetes and to 68% in type 2 diabetes. Clinically significant fibrosis also increased across groups, being 1%, 6% and 12%, respectively. In prediabetes, clinically significant fibrosis was rare in lean or overweight individuals even though most had associated cardiometabolic risk factors, but this increased fourfold in individuals with obesity, particularly when associated with severe adipose tissue and systemic insulin resistance. Having obesity and type 2 diabetes had the highest prevalence of clinically significant fibrosis (16%), and again, mostly if associated with insulin resistance. Most participants with clinically significant fibrosis were in the highest quintiles of Adipo-IR or HOMA-IR (Q4-Q5). CONCLUSIONS/INTERPRETATION: In a real-world cohort from primary care/endocrinology clinics, the prevalence of MASLD increased in a stepwise manner with glycaemic and BMI categories, but the prevalence of fibrosis did not increase in the same stepwise manner and remained rare in the absence of obesity, or in obesity without significant insulin resistance. Prediabetes was a risk factor for significant fibrosis mainly in individuals with obesity and significant insulin resistance. In the context of current guidelines, MASLD risk-stratification may be improved in primary care by establishing the metabolic impact of obesity/diabetes (i.e. assessing insulin resistance by HOMA-IR). |
Diabetologia | 2026 Oct 24 | PubMed |
| 14 |
Maternal mid-pregnancy metabolic profiles and growth trajectories across the first 36 months of life in a UK multi-ethnic birth cohort.
View abstractOBJECTIVES: To investigate the influence of maternal mid-pregnancy metabolomic profiles on offspring anthropometric growth trajectories (weight, length/height, and BMI) across the first 36 months of life in a multi-ethnic birth cohort. METHODS: This longitudinal study analyzed 1423 mother-child pairs from the Born in Bradford cohort. Using NMR, 147 metabolites were quantified in maternal fasting blood samples collected at 26-28 weeks of gestation. Children's growth trajectories for weight, length/height, and BMI across 0-36 months of life were modeled using latent class growth mixture models. Partial least squares discriminant analysis identified key maternal metabolites distinguishing growth trajectories, followed by linear mixed-effects regression examining associations with WHO growth z-scores adjusted for a minimal set of covariates (ethnicity and gestational diabetes mellitus, GDM). RESULTS: Three distinct growth trajectories were identified for each anthropometric measure: normative, intermediate, and non-uniform (accelerated for weight and BMI or faltered for length/height). For each growth trajectory, between 30 and 41 metabolites were required to differentiate between trajectories within each anthropometric measure. Fourteen lipoprotein subclasses were required across weight, length/height, and BMI, with an additional 16 to 31 metabolites required in one or two trajectories. Numerous associations between metabolite levels and change in z-score anrthropometric measures were observed and validated within each growth trajectory (-0.47 to 1.5 for weight; -0.87 to 2.2 for height/length; and -0.85 to 1.8 for BMI; P < 0.05) per unit change in metabolite. South Asian ethnicity and GDM were associated with lower z-scores (-0.214 to -0.212 and -0.044 to -0.041 for weight; -0.061 to -0.045 and -0.104 to -0.101 for length/height; and -0.157 to -0.182 and -0.083 to -0.071 for BMI, respectively). CONCLUSIONS: Metabolomic profiles in mid-pregnancy, especially lipoproteins, characterize observed offspring growth in different directions and/or strengths in various growth trajectories from birth to 36 months of age. |
International journal of obesity (2005) | 2026 Oct 24 | PubMed |
| 15 |
Sodium-Glucose Cotransporter-2 Inhibitor Use in Kidney Transplant Recipients With Post-Transplantation Diabetes Mellitus - A Cross-Sectional Study.
View abstractBACKGROUND: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have proved beneficial effects on cardiovascular risk and preservation of renal function in patients with diabetes mellitus and chronic kidney disease, in addition to their glucose-lowering effects. This study aims to investigate whether SGLT2i was associated with a more favorable metabolic profile in kidney transplant recipients with post-transplantation diabetes mellitus (PTDM). METHODS: In this observational study, patients receiving a kidney transplant between 2007 and 2021 in Norway were identified from the national transplant database. Patients who developed PTDM were identified through new- onset prescription of glucose- lowering treatment after kidney transplantation registered in Norwegian Prescription Database. PTDM patients were categorized whether glucose- lowering treatment included SGLT2i or not during the first 4 years after transplantation. Metabolic parameters at 5 years after transplantation reported to the Norwegian Renal Registry was compared in the 2 patient groups. RESULTS: This observational study included 232 kidney transplant recipients with PTDM. Metabolic parameters at 5 years post-transplantation were compared among the SGLT2i-group (n = 39) and the control group (n = 193); median BMI (27.5 vs. 26.5 kg/m, p = .22), diastolic blood pressure (80 vs. 79 mm Hg, p = .40), systolic blood pressure (129 vs. 132 mm Hg, p = .42), proteinuria-parameters (u-ACR 4.5 vs. 3.5 mg/mmol, p = .33), (u-PCR 26 vs. 13 mg/mmol, p = .29), HbA1c (52 vs. 49 mmol/mol, p = .11) and estimated glomerular filtration rate (eGFR, 61 vs. 56 mL/min/1.73m, p = .20). CONCLUSION: Our study could not demonstrate improved metabolic parameters in PTDM patients treated with SGLT2-inhibitors at 5 years post transplantation. |
Transplantation proceedings | 2026 Oct 24 | PubMed |
| 16 |
Trends in metabolic risk factor control and medication use among adults with type 2 diabetes in Taiwan, 2015-2024.
View abstractBACKGROUND: To evaluate 10-year trends in metabolic control and guideline-directed pharmacotherapy among adults with type 2 diabetes in Taiwan. METHODS: Using Taiwan's National Health Insurance Research Database (2015-2024), we analyzed annual trends in glycated hemoglobin (HbA1c), low-density lipoprotein cholesterol (LDL-C), and medication use. Blood pressure (BP) was assessed via a nationwide Pay-for-Performance registry. Trends were evaluated overall and across subgroups with cardiovascular disease (CVD) or chronic kidney disease (CKD). RESULTS: The treated population expanded from 1.58 to 2.27 million. Target achievement improved significantly: HbA1c <7.0% rose from 42.5% to 55.3%, and LDL-C <100 mg/dL from 54.3% to 69.0% (both p-trend <0.001). Among patients with all three measurements available, triple-factor control reached 18.2% by 2024. These gains coincided with rapid sodium-glucose cotransporter-2 inhibitor (SGLT2i) uptake (from 3.3% in 2016 to 38.0% in 2024) and increased statin use. However, 23.5% of young adults (20-44 years) maintained poor glycemic control (HbA1c ≥ 8.5%). SGLT2i use was higher in patients with CVD (43.1%) or CKD (43.8%) than in those without the respective conditions (34.7% and 36.6%), while glucagon-like peptide-1 receptor agonist (GLP-1RA) use remained below 4%. CONCLUSIONS: Metabolic control in Taiwan improved substantially alongside adoption of newer therapies. Gaps among younger adults and high-risk cohorts highlight the need for targeted, risk-stratified management. |
Journal of the Formosan Medical Association = Taiwan yi zhi | 2026 Oct 24 | PubMed |
| 17 |
Association of insulin resistance surrogate indices with multimorbidity among postmenopausal women: cross-sectional and longitudinal evidence from NHANES and CHARLS with machine learning-based evaluation.
View abstractBACKGROUND: Insulin resistance (IR) is closely linked to multiple chronic diseases, but the comparative associations and discriminatory performance of different IR surrogate indices for multimorbidity in postmenopausal women remain unclear. METHODS: We analyzed postmenopausal women from NHANES and CHARLS. Eleven IR surrogate indices were evaluated using weighted logistic regression in NHANES and Cox proportional hazards models in CHARLS. Dose-response relationships were examined using restricted cubic splines. Discriminatory performance was assessed using ROC analyses, including time-dependent ROC analyses for CHARLS. Machine learning models were additionally developed using NHANES data to classify prevalent multimorbidity. RESULTS: In NHANES, most IR surrogate indices were positively associated with prevalent multimorbidity, whereas estimated glucose disposal rate (eGDR) showed a strong inverse association (OR = 0.28, 95% CI 0.21-0.37, p < 0.001). In CHARLS, eGDR was also inversely associated with incident multimorbidity in both baseline (HR = 0.78, 95% CI 0.73-0.84, p < 0.001) and cumulative analyses (HR = 0.67, 95% CI 0.58-0.77, p < 0.001). eGDR showed the highest discrimination among the evaluated indices in NHANES (AUC = 0.809) and in the CHARLS cumulative analysis (AUC = 0.634). Machine learning analysis in NHANES identified eGDR as the most important feature, and the optimal support vector machine model achieved an AUC of 0.835. Sensitivity analyses excluding hypertension, diabetes, and dyslipidemia attenuated the eGDR associations in CHARLS. CONCLUSIONS: Multiple IR surrogate indices were associated with multimorbidity among postmenopausal women, with eGDR showing the most consistent inverse association across analyses. These indices may assist population-level risk stratification, although their clinical utility requires further external validation. |
Experimental gerontology | 2026 Oct 24 | PubMed |
| 18 |
Sex differences in prevalence normalized mortality and risk attributable mortality indices for type 2 diabetes across the European Union.
View abstractAIMS: To characterize sex-specific prevalence-normalized mortality and modelled risk-attributable mortality patterns for type 2 diabetes across the 27 European Union member states METHODS: We conducted an ecological analysis of Global Burden of Disease 2023 modelled estimates at two benchmark years, 2011 and 2021. Age-standardized mortality and prevalence rates were combined as a prevalence-normalized mortality ratio. Risk-attributable mortality was normalized to prevalence as a risk-attributable prevalence-normalized mortality index. Approximate intervals assumed independence between numerator and denominator and between sexes; country-level sex comparisons used Benjamini-Hochberg false discovery rate correction. RESULTS: The unweighted country mean age-standardized mortality rate was higher in 2021 than in 2011, changing from 12.02 to 14.32 per 100,000 in men and from 8.84 to 10.08 per 100,000 in women; the corresponding prevalence means increased from 4,131.6 to 4,660.2 and from 2,875.3 to 3,178.6 per 100,000. Mean prevalence-normalized mortality changed modestly. No country-level sex comparison remained significant after false-discovery-rate correction. Tobacco-related indices were higher in men in all 27 countries and met the FDR criterion in 23 under the independence approximation; no other risk family contained corrected significant differences. CONCLUSIONS: Across-country means describe member states rather than the population-weighted European Union. The tobacco-related index was consistently higher in men, a pattern compatible with established sex differences in tobacco exposure. Statistical evidence depends on unverified covariance assumptions. All indices are ecological summaries of modelled rates and must not be interpreted as individual mortality probabilities, causal effects, or evidence of independent sex-specific biological mechanisms. |
Diabetes research and clinical practice | 2026 Oct 24 | PubMed |
| 19 |
Practical Prevention of Heart Failure Across Stages A and B: A Scientific Statement From the Japanese Heart Failure Society.
View abstractHeart failure (HF) is a growing health problem in Japan, associated with substantial morbidity, mortality, recurrent hospitalization, impaired quality of life, and increasing healthcare costs. Early prevention before the onset of signs and symptoms has therefore become a major priority in cardiovascular medicine. This scientific statement from the Japanese Heart Failure Society provides practical prevention strategies for patients with HF Stage A and Stage B in Japan. Particular emphasis is placed on biomarker-guided screening using brain (B-type) natriuretic peptide (BNP) and N-terminal pro-BNP (NT-proBNP) to facilitate earlier detection of Stage B (pre-HF) and identification of patients at increased risk of progression to symptomatic HF. The statement summarizes evidence-based management of major cardiovascular-kidney-metabolic disorders associated with HF development, including hypertension, diabetes mellitus, chronic kidney disease, obesity, coronary artery disease, left ventricular dysfunction, valvular heart disease, and atrial fibrillation. It also addresses disease-specific approaches for optimizing blood pressure, glycemic control, renal protection, lipid management, and weight reduction. Preventive strategies include lifestyle modification, pharmacological therapy, serial reassessment of natriuretic peptide levels, and appropriate use of cardiovascular imaging and timely specialist referral. Because many patients at risk for HF are managed outside specialized cardiovascular centers, practical pathways for collaboration between cardiologists and non-cardiologist physicians are essential. The importance of timely referral, shared risk recognition, and multidisciplinary care is therefore emphasized. Implementation of clinically applicable prevention strategies may help reduce progression to symptomatic HF, facilitate earlier therapeutic intervention, and improve long-term cardiovascular outcomes. |
Journal of cardiac failure | 2026 Oct 24 | PubMed |
| 20 |
Bergenin attenuates diabetic cardiomyopathy by inhibiting oxidative stress and ferroptosis through modulation of the YAP signaling axis.
View abstractAIMS: Diabetes mellitus-associated cardiac dysfunction arises from metabolic imbalance, oxidative stress, inflammation, maladaptive remodeling, and impaired cardiac performance. Bergenin (BER), a naturally occurring small molecule with antioxidant, anti-inflammatory, and metabolic regulatory properties, has shown therapeutic potential; however, its role in diabetic cardiomyopathy (DCM) remains unclear. This study investigated the cardioprotective effects of BER in DCM, with particular emphasis on oxidative stress, the Hippo-Yes-associated protein (YAP), and ferroptosis signaling axis. MATERIALS AND METHODS: DCM was induced in rats using a high-fat diet combined with low-dose streptozotocin (STZ). Diabetic rats received BER (25 or 50 mg/kg/day) or empagliflozin (10 mg/kg/day). Cardiac function was evaluated by echocardiography, followed by histopathological and molecular analyses. To further investigate the underlying mechanisms, H9c2 cardiomyoblasts exposed to high glucose were used for in vitro assessment of oxidative stress, Hippo-YAP signaling, and ferroptosis-related markers. KEY FINDINGS: In vivo, BER treatment significantly improved cardiac function, attenuated histopathological injury, and reduced cardiomyocyte hypertrophy and fibrosis in diabetic rats. Consistent with these findings, in vitro, BER reduced reactive oxygen species generation, restored mitochondrial integrity, and prevented high glucose-induced injury in H9c2 cells. Mechanistically, BER modulated YAP signaling and suppressed ferroptosis-related changes. YAP silencing attenuated the protective effects of BER, supporting a critical role for YAP in mediating its anti-ferroptotic effects. SIGNIFICANCE: These findings demonstrate that BER exerts cardioprotective effects against diabetes-associated cardiac dysfunction and provide mechanistic evidence implicating the YAP-ferroptosis axis in this protection. Further studies are warranted to establish its translational potential. |
Life sciences | 2026 Oct 24 | PubMed |
| 21 |
Precision medicine approaches in diabetic cardiomyopathy: from molecular mechanisms to personalized therapeutic strategies.
View abstractDiabetic cardiomyopathy (DCM) is a distinct myocardial disease defined by the existence of abnormal myocardial structure and performance in diabetes mellitus patients without hypertension and coronary artery disease. DCM has been identified as a major cause of heart failure, hospitalisation and cardiovascular mortality with increasing global burden of diabetes. However, there is a large interindividual variation in disease susceptibility, disease progression and response to therapy, highlighting the limitations of conventional management strategies that are applied uniformly. Precision medicine provides a transformational approach through the integration of genomic, molecular, imaging, clinical and lifestyle data to allow for personalized risk assessment, early diagnosis, prognostication and treatment. This review presents the recent advances in the field of precision medicine for DCM with a focus on the molecular pathological mechanisms including metabolic disorders, oxidative stress, mitochondrial dysfunction, inflammation, fibrosis and microvascular injury. We discuss the relevance of genomics, pharmacogenomics, transcriptomics, proteomics, metabolomics, lipidomics and epigenomics in the context of disease heterogeneity and identification of novel therapeutic targets. Emerging biomarkers including circulating microRNAs, non-coding RNAs, inflammatory mediators, fibrosis-related markers and extracellular vesicles are discussed for their potential in personal diagnosis and prognosis. We also consider the increasing role of advanced cardiac imaging, digital phenotyping, wearable technologies, artificial intelligence, and machine learning in enhancing early detection and clinical decision-making. In this review, the therapeutic advances, including sodium-glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, anti-fibrotic therapies, mitochondrial-targeted interventions, regenerative medicine, gene therapy, and RNA-based therapeutics, are discussed, with a focus on the precision medicine approach. Finally, we present current challenges in data integration, clinical validation, cost-effectiveness, and ethical issues, and highlight future directions in digital twins, multi-omics integration, and AI-driven personalized cardiology. The combination of these technologies has the potential to revolutionize the prevention and management of diabetic cardiomyopathy and improve cardiovascular outcomes in patients with diabetes. |
Journal of molecular and cellular cardiology | 2026 Oct 24 | PubMed |
| 22 |
Evaluating shared gene prioritization for type 2 diabetes and FinnGen R10 chronic periodontitis.
View abstractOBJECTIVE (S): To assess whether selected genome-wide association studies support shared gene-level prioritization between type 2 diabetes (T2D) and periodontitis. DESIGN: European DIAMANTE T2D and FinnGen R10 chronic periodontitis summary statistics were analyzed using a custom whole-gene test accounting for linkage disequilibrium, with trait-specific Bonferroni correction. Published Stage III/IV Grade C periodontitis gene results were compared descriptively. Secondary analyses used multi-ancestry DIAMANTE statistics to construct minimum-P window labels, with a relaxed label selected after threshold inspection. Annotation-based elastic-net models were evaluated in repeated nested cross-validation before and after excluding 13 predictors dependent on locus-to-gene scores. Negative matching retained dependence on these scores. RESULTS: Among 19,280 eligible T2D genes and 19,378 periodontitis genes, 683 T2D genes crossed the corrected threshold (353 using point probabilities and 330 using upper bounds); none crossed for periodontitis. No gene met both cutoffs among 19,275 commonly eligible genes. Three published periodontitis entries crossed the comparison cutoff (0.05/19,496), representing FCER1G and two SIGLEC5 identifiers; none met the primary T2D cutoff. The relaxed window label yielded 50 positive genes, evaluated with 250 matched negatives per panel. Across ten elastic-net configurations, mean pooled area under the receiver operating characteristic curve was 0.527 (range, 0.452-0.583) with full predictors and 0.482 (range, 0.437-0.528) after predictor exclusion; mean pooled average precision was 0.205 and 0.165, respectively. Genome-wide scoring was not performed. CONCLUSIONS: The primary analysis did not establish shared gene-level associations. Secondary models did not justify genome-wide scoring of unlabeled genes. The findings do not exclude shared genetic susceptibility. |
Archives of oral biology | 2026 Oct 20 | PubMed |
| 23 |
Nurse-supported smartphone diabetes self-management in older adults.
View abstractWhile medications, healthy diet, and weight management are essential elements of any type 2 diabetes mellitus (T2DM) treatment plan, prescribing physical activity is a key aspect of person-centered diabetes management. Smart phone diabetes applications (apps) positively affect disease self-management in older adults. To optimize technology in healthcare, a 12-week DNP project introduced a free app titled Glucose Buddy Diabetes Tracker© and coaching to a population of adults who were age 60-75 and diagnosed with T2DM and had an elevated HgA1c of 7% or higher. A pre and posttest analyzed self-reported activity levels and quality of life measures after the digital health intervention. Although the sample was small, the results were promising. Data showed that self-reported quality of life improved, and sedentary time decreased by as much as three hours. This study captured the unique challenges and barriers associated with recruitment and active participation with digital health technology in older adults. |
Geriatric nursing (New York, N.Y.) | 2026 Oct 24 | PubMed |
| 24 |
TRIM65 deficiency exacerbates HFD-induced obesity in mice associated with elevated adipose tissue inflammation and lipid accumulation.
View abstractObesity is linked to metabolic and cardiovascular complications, such as atherosclerosis, type 2 diabetes (T2DM), and hypertension. Despite current therapies alleviate certain clinical manifestations, effective disease-modifying targets remain scarce. TRIM65 (tripartite motif-containing 65) has been linked to carcinogenesis, immune modulation, and inflammatory responses, yet its role in obesity remains unknown. Here, we aimed to elucidate the pathophysiological function of TRIM65 in obesity and to reveal the molecular networks regulating this process. Our results demonstrated a significant decrease in TRIM65 expression under obese conditions. Notably, TRIM65 knockout mice exhibited exacerbated high fat diet (HFD)-induced obesity, as evidenced by marked increases in body and white adipose tissue (WAT) weight, enlarged adipocyte sizes, elevated systemic and tissue inflammation, and impaired glucose and insulin tolerance. Furthermore, knockout of TRIM65 aggravated HFD-induced dyslipidemia, hepatic steatosis, and liver injury. Mechanistically, TRIM65 deficiency triggered the ERK1/2-NF-κB signaling cascade, leading to a pro-inflammatory environment and aggravating insulin resistance. Simultaneously, TRIM65 deficiency enhanced the expression of adipogenic and lipogenic genes while diminishing that of lipolytic genes, culminating in increased lipid accumulation. Collectively, TRIM65 is established by our findings as a pivotal negative regulator that coordinately curbs lipid synthesis and inflammatory responses, thereby positioning it as an attractive therapeutic target for obesity and its metabolic complications. |
International immunopharmacology | 2026 Oct 24 | PubMed |
| 25 |
High Prevalence of Pruritus, Fatigue, and Sleep Disorders in MASLD Negatively Affects Health-related Quality of Life and Work Productivity.
View abstractBACKGROUND: Metabolic dysfunction-associated steatotic liver disease (MASLD) is associated with health-related quality of life (HRQL) impairment, which can be exacerbated by pruritus, fatigue, and/or sleep disorders. We assessed the prevalence of significant pruritus, fatigue, and sleep disorders in patients with MASLD and evaluated their association with HRQL and work productivity loss. METHODS: Patients with MASLD were prospectively enrolled into the Global NAFLD/MASLD Registry. Clinical and HRQL (per CLDQ-MASH and WPAI:SHP questionnaires) data were analyzed according to the presence of significant pruritus, significant fatigue, and sleep disorders. RESULTS: A total of 8034 patients with MASLD from 39 countries (age 54±12 years, 46% male, 50% type 2 diabetes, 39% advanced fibrosis) were included. At baseline, 25% reported significant pruritus, 35% significant fatigue, and 34% sleep disorders, and 10% had all 3 symptoms. Patients with fatigue, pruritus, or sleep disorder were more likely to be female, have higher BMI, more metabolic comorbidities, and greater psychiatric burden. At 1-year follow-up, over half of the patients with baseline symptoms continued to experience them, and 14% to 18% developed de novo symptoms. Multivariate analyses showed that significant pruritus and sleep disorders each independently predicted fatigue [OR=9.51 (8.0-11.3)] when both conditions were present. Pruritus was a strong predictor of sleep disorders [OR=2.90 (2.6-3.3)]. All 3 conditions, especially fatigue, were independently associated with significantly impaired HRQL and work productivity loss. CONCLUSION: Clinically significant fatigue, pruritus, and sleep disorders are common in MASLD, having a negative impact on HRQL and a substantial economic burden. |
Journal of clinical gastroenterology | 2026 Oct 22 | PubMed |

